Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Table 5 Serum clinical safety markers, part II

Variable	T1	T2	T3	Time*group	Timegroupgender
Urea Nitrogen (mg/dL)
PLA	16 ± 4	15 ± 4	16 ± 5	Time p = 0.89	GTGe p = 0.39
LD	14 ± 3	14 ± 3	15 ± 3	G*T p = 0.34
HD	15 ± 4	13 ± 4	14 ± 3	G*T p = 0.34
Creatinine (mg/dL)
PLA	1.18 ± 0.2	0.96 ± 0.2	0.97 ± 0.2	Time p = 0.33	*GTGe* p = 0.046
LD	0.97 ± 0.1	1.02 ± 0.2	1.03 ± 0.2 ^‡	G*T p = 0.06
HD	0.99 ± 0.2	1.01 ± 0.2	1.05 ± 0.2	G*T p = 0.06
Sodium (mmoL)
PLA	140.65 ± 3	139.85 ± 2	140.95 ± 2	Time p = 0.007	GTGe p = 0.84
LD	141.22 ± 2	140.17 ± 2	140.95 ± 3	G*T p = 0.67
HD	141.19 ± 3	139.95 ± 2 ^†	140.24 ± 2	G*T p = 0.67
Potassium (mmoL)
PLA	4.9 ± 0.4	4.7 ± 0.6	4.9 ± 0.5	Time p = 0.22	GTGe p = 0.99
LD	5.0 ± 0.6	4.8 ± 0.4	4.9 ± 0.5	G*T p = 0.97
HD	4.9 ± 0.4	4.8 ± 0.4	4.9 ± 0.4	G*T p = 0.97
Chloride (mmoL)
PLA	105.60 ± 2	104.45 ± 2 ^†	105.00 ± 2	Time p = 0.006	GTGe p = 0.60
LD	105.89 ± 2	105.33 ± 2	104.84 ± 2	G*T p = 0.78
HD	105.24 ± 2	104.33 ± 2 ^†	104.57 ± 2	G*T p = 0.78
Calcium (mg/dL)
PLA	9.7 ± 0.5	9.5 ± 0.4	9.6 ± 0.4	Time p = 0.37	GTGe p = 0.74
LD	9.6 ± 0.3	9.6 ± 0.4	9.6 ± 0.3	G*T p = 0.20
HD	9.8 ± 0.3	9.7 ± 0.4	9.7 ± 0.3	G*T p = 0.20
Carbon Dioxide (mmoL)
PLA	24 ± 2	25 ± 2	24 ± 2	Time p = 0.65	GTGe p = 0.95
LD	26 ± 2	26 ± 2	25 ± 2	G*T p = 0.85
HD	25 ± 2	25 ± 2	25 ± 2	G*T p = 0.85

Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Symbols: ^‡, increase from corresponding T1 value within the male TC-LD group (p < 0.05); ^†, different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed